protac-design-agent — independently scanned and version-tracked by SaferSkills.
SaferSkills independently audited protac-design-agent (Agent Skill) and scored it 100/100 (green). The audit ran 55 deterministic rules across Security, Supply Chain, Maintenance, Transparency, and Community; it found 0 high-severity and 0 lower-severity findings. The full rule-by-rule trace and per-finding evidence are below. Free, methodology-open.
Findings & checks · 0 flagged
Every scanned point with the score it earned and what moved between them.
First recorded scan — no prior version to compare against.
The primary manifest — the file an agent reads to learn what this artifact does.
The PROTAC Design Agent provides AI-assisted design of Proteolysis Targeting Chimeras (PROTACs) for targeted protein degradation. It integrates machine learning for ternary complex prediction, linker design, E3 ligase selection, and ADMET optimization to accelerate degrader drug discovery for oncology and other therapeutic areas.
| Component | Function | Optimization Target |
|---|---|---|
| Warhead | Binds target protein (POI) | Affinity, selectivity |
| E3 Ligand | Recruits E3 ubiquitin ligase | CRBN/VHL binding |
| Linker | Connects warhead to E3 ligand | Length, flexibility, solubility |
| E3 Ligase | Ligand | Tissue Expression | Advantages |
|---|---|---|---|
| CRBN | Thalidomide analogs | Ubiquitous | Well-characterized |
| VHL | VHL ligands | Ubiquitous | High selectivity |
| MDM2 | Nutlin analogs | Variable | p53-independent |
| IAP | SMAC mimetics | High in cancer | Dual mechanism |
| DCAF15 | Indisulam | Variable | Novel chemistry |
User: "Design a PROTAC to degrade BRD4 using CRBN as the E3 ligase, optimizing for oral bioavailability."
Agent Action:
python3 Skills/Drug_Discovery/PROTAC_Design_Agent/design_protac.py \
--target BRD4 \
--target_structure pdb:3MXF \
--warhead_smiles "JQ1_core_smiles" \
--e3_ligase CRBN \
--linker_library peg,alkyl,piperdine \
--linker_length_range 4,12 \
--optimize_oral true \
--output protac_designs/| Parameter | Options | Consideration |
|---|---|---|
| Length | 2-20 atoms | Ternary complex geometry |
| Chemistry | PEG, alkyl, piperazine, triazole | Solubility, stability |
| Rigidity | Flexible vs constrained | Entropic penalty |
| Attachment | Connectivity points | Exit vector matching |
| MW Contribution | Varies | Total MW impact |
| Output | Description | Format |
|---|---|---|
| PROTAC Structures | Designed molecules | .sdf, SMILES |
| Ternary Models | POI-PROTAC-E3 complexes | .pdb |
| Predicted DC50 | Degradation potency | .csv |
| Predicted Dmax | Maximum degradation | .csv |
| ADMET Predictions | Solubility, permeability, etc. | .csv |
| Synthesis Routes | Retrosynthetic analysis | .json |
| Ranking | Prioritized designs | .csv |
| Metric | Definition | Target |
|---|---|---|
| DC50 | Concentration for 50% degradation | <100 nM |
| Dmax | Maximum degradation achieved | >90% |
| Kinetics | Time to half-degradation | <4 hours |
| Selectivity | Off-target degradation | Minimal |
| Hook Effect | High-dose attenuation | Minimal |
Ternary Complex Prediction:
Degradation Modeling:
Linker Optimization:
ADMET Prediction:
| PROTAC | Target | Phase | E3 Ligase |
|---|---|---|---|
| ARV-471 | ER | Phase 3, NDA filed | CRBN |
| ARV-110 | AR | Phase 2 | CRBN |
| BGB-16673 | BTK | Phase 3 | CRBN |
| NX-2127 | BTK | Phase 2 | CRBN |
| KT-474 | IRAK4 | Phase 2 | CRBN |
| Factor | PROTAC Challenge | Solution |
|---|---|---|
| High MW | Poor permeability | Chameleonicity |
| Low Solubility | Limited exposure | Solubilizing groups |
| Hook Effect | Reduced efficacy at high doses | Optimize binding balance |
| E3 Saturation | Competition with other PROTACs | Target expression |
| Property | Challenge | Approach |
|---|---|---|
| Permeability | High MW limits | Intramolecular H-bonds |
| Solubility | Lipophilicity | Polar linker groups |
| Metabolic Stability | Linker metabolism | Stable chemistries |
| Clearance | High metabolism | Optimize logD |
| QC Check | Threshold | Rationale |
|---|---|---|
| Ternary Complex Score | >0.7 | Productive complex |
| Linker Strain | <5 kcal/mol | Favorable geometry |
| ADMET Score | >0.5 | Drug-like properties |
| Synthetic Accessibility | <5 | Feasible synthesis |
AI Group - Biomedical AI Platform
~30 seconds. Free. No account. Every finding cites a rule and a line of evidence.